HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Warns Pharmagel, Updates Webpage On Drug-Claim Violations

This article was originally published in The Rose Sheet

Executive Summary

Pharmagel's name and billing as "pharmaceutical grade anti-aging skin care" may have drawn FDA's attention, but benefits cited in the agency's warning letter – including collagen- and elastic-building claims – are consistent with FDA's enforcement action against other companies so far in 2015.


Related Content

FDA Warning Letter Recipients: Where Are Their Claims Now?
House Cosmetics Bill Seeks Broad Federal Preemption, Revised 'Cosmetic' Definition
FDA's Final IND Guidance Has Industry On Edge: What Happens Next?
FDA Reels In Golden Caviar For Fishy Skin-Care Claims
FDA Shows Skin Authority Who’s Boss With Warning For Drug Claims
FDA Warns Former AAD President For DNA Eye Renewal Claims
Will Cosmeceutical Pioneer Turn Its Wagons Around? FDA Warns Strivectin
FTC Settles With DermaTend, DERMAdoctor Firms For Unsupported Claims



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts